2. Disease Areas
  3. Cancer
  4. Breast Cancer
  5. HER-2 Positive Breast Cancer

HER-2 Positive Breast Cancer

HER2-positive breast cancer is a subtype of breast cancer characterized by overexpression of the human epidermal growth factor receptor 2 (HER2) protein, which promotes rapid cancer cell growth. It tends to be more aggressive, grow faster, and has a higher risk of recurrence compared to HER2-negative breast cancer. Approximately 20-30% of breast cancers are HER2-positive. Common signs include a new lump or thickening in the breast, changes in nipple appearance such as inversion, and alterations in breast size or shape. The disease is associated with increased tumor progression and metastasis potential, making targeted therapies essential for effective treatment.

HER-2 Positive Breast Cancer (2):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0015
    Paclitaxel 33069-62-4 99.97%
    Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy.
    Paclitaxel
  • HY-103043
    Pz 285 1400998-20-0
    Pz 285 is an anti-cancer agent. Pz 285 shows significant inhibitory effect on the viability of MDA-MB-231 breast cancer cells, with an IC50 of 15.0 μM. Pz 285 exhibits remarkable antitumor effects in the mouse tumor xenograft model constructed with highly lung-metastatic MDA-MB-231 LM24 Her2+ breast cancer cells. Pz 285 can be used for the study of breast cancer, especially metastatic breast cancer.
    Pz 285